biocluster of excellence
GenoTher’s missions
A biocluster of excellence serving the needs of genetic medecine project leaders, helping them to develop new therapies and meet their development challenges.
Accelerate therapeutic and technological innovation
Provide access to cutting edge technology platforms
Foster training and talent development
Support high-potential biotech company growth
Enable public-private strategic partnerships
Strengthen international visibility and outreach
GenoTher has been awarded “Biocluster” label, in the framework of the “France 2030” investment programs, showing France priorization of the development of genetic medecine as a strategic area of therapeutic innovation.
Technology
Platforms & services
An integrated technological ecosystem
Preclinical platforms (vector, gene editing, LNP, immune response)
Bioproduction (non-GMP & GMP manufacturing)
Clinical & data platforms (trial optimization, medtech)
%20-%20GenoTher%20-%2025%2003%202026_edited.png)
%20-%20GenoTher%20-%2025%2003%202026_edited.png)
2,000+
scientists & clinicians
10,000+
publications
2,000+
patents
40+
Licences and clinical programs
15+
Startups created
A world-class ecosystem
Ecosystem strengths
A powerful network of leaders
Founders, partners & stakeholders
R&D leader since gene therapy inception. Founding research and IP for Zolgensma. 13 products in the clinic internationally.
Pioneer US gene therapy company and member of the Roche Group. Launched the first FDA approved gene therapy for a genetic disease.
38 hospitals covering all medical expertises. Largest group of university hospitals in Europe 2 GMP platforms. Owner of million patient data.
1st French biocampus dedicated to genomics derived industrial applications, and company creation.
Worldwide Ranking for Genomics Research. Dedicated Applied Mathematics and Computer sciences Robotics for production.
EU’s manufacturing leader in gene therapies. 10,000 m2 of GMP manufacturing capacity.
Among the largest research academic institutions in the world for medicine and biology. Leader of 3 flagship actions of the national biotherapies-bioproduction strategy.
Our action field
Genetic medicine: a strategic area of therapeutic innovation
One of the most dynamic therapeutic field
78 genetic medicines approved, of which 48 in the last 5 years
Multiple therapeutical applications
Neuromuscular, Cardiovascular, Diabetes and metabolism, Oncology
CNS (Central Nervous System), Infections, Opthtalmology
Blood disorders, Immune disorders
Vaccines, Kidney...
France at the origins of many breakthrough innovations
Marketed Products: Zolgensma®, Skysona®, Zynteglo®, Luxturna®. Technological Contributions: CAR-T, AAV.
41 currently approved gene therapies worldwide
21 oncology, 18 rare diseases, 2 others
37 currently approved RNA gene therapies worldwide
20 rare diseases, 14 infectious diseases, 2 ophthalmology, 2 others
+3 000 genetic medicine products
including genetically modified cell therapies and RNA therapies
